

Amendment to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application:


In the claims:

Please amend the claims as follows:

1. **(Currently Amended)** A method of preparing a lipid membrane, the method comprising:

(a) providing a lipid membrane comprising a lipid monolayer, bilayer or multilayer;

(b) providing a plurality of silyl lipid molecules integrally-associated with the lipid membrane of (a), wherein each silyl lipid molecule comprises at least one silanol group; and wherein said silyl lipid molecule is of the formula:



wherein:

R is selected from a group consisting of C₁-C₅₀ alkyl;

R' is selected from a group consisting of (CH₂)_qA and OSiR₃;

A is selected from a group consisting of hydrogen, COO⁻, OH, COOH, N⁺R₁R₂R₃, NHR'', SH, SR'' and C₁-C₅₀ alkyl;

R₁, R₂, R₃ and R'' are selected from a group consisting of (CH₂)_qCH₃ and (CH₂)_qSi(OR)₃;

q is a number from 1 to 50;

n is a number from 1 to 4; and

m is a number from zero to 3; and

(c) cross-linking, via a siloxane bond, at least one silanol group from a first silyl lipid with at least one silanol group from a second silyl lipid; and

(d) further cross-linking the silyl lipids to an encapsulation material.

2. (Previously Presented) A method of preparing an encapsulated Langmuir lipid membrane, the method comprising:

(a) providing a lipid monolayer, bilayer or multilayer membrane comprising a plurality of silyl lipid molecules integrally-associated with the lipid monolayer, bilayer or multilayer membrane, wherein each silyl lipid molecule comprises at least one silanol group;

(b) cross-linking, via a siloxane bond, at least one silanol group from a first silyl lipid with at least one silanol group from a second silyl lipid;

(c) providing an upper layer of encapsulation material;
and


(d) providing a lower layer of encapsulation material or a lower layer of supporting substrate,

wherein the lipid monolayer, bilayer or multilayer membrane is positioned between the upper layer and the lower layer.

3. (Cancelled)

4. **(Currently Amended)** A method of modifying the pH of a patients blood during renal dialysis ~~a fluid comprising plasma and suspended formed elements~~, the method comprising contacting the patients blood ~~the fluid~~ with a lipid membrane prepared by the method claim 2, wherein the lipid membrane is associated with an acidic compound capable of modifying the pH of the blood fluid.

5. (Previously Presented) The method of claim 2 wherein said silyl lipid is of the formula:



wherein:

R is selected from a group consisting of C₁-C₅₀ alkyl;

R' is selected from a group consisting of (CH₂)_qA and OSiR₃;

A is selected from a group consisting of hydrogen, COO⁻, OH, COOH, N⁺R₁R₂R₃, NHR'', SH, SR'' and C₁-C₅₀ alkyl;

R₁, R₂, R₃ and R'' are selected from a group consisting of (CH₂)_qCH₃ and (CH₂)_qSi(OR)₃;

q is a number from 1 to 50;









n is a number from 1 to 4; and

m is a number from zero to 3.

6. (Previously Presented) The method of claim 2 wherein said encapsulation material is an inorganic-organic hybrid mixture sol.

7. (Cancelled)

8. (Previously Presented) The method of claim 6 wherein said hybrid mixture sol is prepared from precursor molecules of the following formula:



9. (Previously Presented) A method for stabilizing a lipid membrane, the method comprising:

a) providing a lipid membrane comprising:

- i) a lipid monolayer, bilayer or multilayer;
- ii) phospholipids; and
- iii) protein,


b) providing a plurality of silyl lipid molecules integrally-associated with the lipid membrane of a), wherein each silyl lipid molecule comprises at least one silanol group; and

c) cross-linking, via a siloxane bond, at least one silanol group from a first silyl lipid with at least one silanol group from a second silyl lipid, thereby stabilizing the lipid vesicle.

10. (Canceled)

11. (Canceled)

12. (Previously Presented) The method of claim 9, wherein the silyl lipid is of the formula:



wherein:

R is selected from a group consisting of C₁-C₅₀ alkyl;

R' is selected from a group consisting of (CH₂)_qA and OSiR₃;

A is selected from a group consisting of hydrogen, COO⁻, OH, COOH, N⁺R₁R₂R₃, NHR'', SH, SR'' and C₁-C₅₀ alkyl;

R₁, R₂, R₃ and R'' are selected from a group consisting of (CH₂)_qCH₃ and (CH₂)_qSi(OR)₃;

q is a number from 1 to 50;

n is a number from 1 to 4; and

m is a number from zero to 3.

13. (Previously Presented) The method of claims 1 or 9, wherein the lipid membrane forms a vesicle.

14. (**Currently Amended**) The method of claims ~~1 or~~ 9, wherein the silyl lipids are further cross-linked to an encapsulation material.

15. (**Currently Amended**) The method of claims 1 or 14, wherein the encapsulation material is selected from the group consisting of sol-gel matrix, hybrid mixture sol-gel matrix and glass matrix.

16. (Previously Presented) The method of claim 14, wherein the sol-gel matrix is an inorganic-organic hybrid mixture sol.

17. (Previously Presented) The method of claim 15 wherein the hybrid mixture sol-gel matrix is prepared from precursor molecules of the following formula:

